Harvard Bioscience (NASDAQ: HBIO) — Perfil da empresa, notícias e dados financeiros
Harvard Bioscience develops life science tools for research, aiming to enhance efficiency and innovation in drug discovery.
Harvard Bioscience
Harvard Bioscience (NASDAQ:HBIO) specializes in the development, manufacture, and marketing of a broad range of life science tools and equipment, catering primarily to research and drug discovery sectors. Its diverse product portfolio includes solutions for electrophysiology, cell analysis, molecular imaging, and physiology, wherein it consistently aims at enhancing the efficiency and accuracy of scientific researchers worldwide. The company's objectives revolve around innovation and expansion within the life sciences field, striving to meet the evolving needs of their global customer base through continuous product development and strategic acquisitions. Harvard Bioscience's operational footprint extends internationally, highlighting its commitment to advancing scientific research across borders.
Resumo
Operações
Produtos e/ou serviços de Harvard Bioscience
- Life science research instruments, including molecular, cell biology, and physiology analysis tools, tailored to advance scientific understanding and discovery.
- Preclinical surgical systems and instruments, designed for precision and reliability, supporting researchers and surgeons in developing new surgical techniques and medical devices.
- Fluidics systems and components, offering precise control for a variety of life science applications, including drug discovery, diagnostics, and high-throughput screening.
- Animal physiology monitoring equipment, enabling researchers to measure critical physiological parameters in vivo, vital for preclinical studies and new drug development.
- Cell and tissue analysis solutions, providing researchers with tools for detailed examination and analysis, crucial for understanding disease mechanisms and developing therapies.
- Electrophysiology and neural signal recording devices, used for advanced research in neuroscience, helping to unravel the complexities of the brain and nervous system.
equipe executiva do Harvard Bioscience
- John DukePresident, CEO, Director & Member of Scientific Advisory Board
- Mark T. FrostCFO, Treasurer, Principal Financial Officer & Principal Accounting Officer
- Lori PackerVice President of Global People Operations
- David PanzarellaSenior Vice President of Commercial
- Kathryn FlynnCorporate Controller
- David SiroisDirector of Corporate Accounting & SEC Reporting
Últimas notícias sobre a Harvard Bioscience
Principais indicadores financeiros
Resultados divulgados pela Harvard Bioscience, em USD.
- Cap. de mercado
- 38 mi
- Receita (TTM)
- 87,8 mi
- P/L
- —
- LPA (diluído, TTM)
- -2.3
- Dividend yield
- —
- Margem de lucro
- -11.9%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 86,6 mi | -629 mil | -56,7 mi | |
| 94,1 mi | -6,2 mi | -12,4 mi | |
| 112,3 mi | 1,9 mi | -3,4 mi | |
| 113,3 mi | -6,9 mi | -9,5 mi |